

VU Research Portal

Critical Challenges and Opportunities for Probiotic Innovators

Flach, J.

2020

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Flach, J. (2020). *Critical Challenges and Opportunities for Probiotic Innovators: Advancing Research and Development on Live Microorganisms for the Promotion of Human Health*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

TABLE OF CONTENTS

Summary:	5
Chapter 1. Introduction	
1.1 The Human Microbiota	18
1.1.1 Colonization by microbes	18
1.1.2 Gut microbiota composition	18
1.1.3 Personal microbiota	18
1.1.4 Mutualistic relationships	20
1.1.5 Dysbiosis & disease	21
1.2 Probiotics	22
1.2.1 Microbial intervention	22
1.2.2 Probiotic applications	22
1.2.3 Clinical evidence	23
1.2.4 Mechanism of action	24
1.2.5 Prebiotics & synbiotics	26
1.2.6 Safety	26
1.3 Probiotic market	26
1.3.1 Products & markets	26
1.3.2 Regulations & health claims	27
1.4 Innovation process	28
1.4.1 Defining innovation	28
1.4.2 Microbiota Valorisation & Tech Transfer Cycle	29
1.5 Problem statement & Research design	30
1.5.1 Which critical challenges do innovators face when developing probiotic applications?	32
1.5.2 What are the barriers and opportunities for bowel habit improvement in nursing homes with probiotic intervention?	33
1.5.3 What are the perceptions of physicians and patients towards probiotics?	33
1.5.4 How should research be prioritized for health claim approval in the adult population?	34
1.6 Authored work	36
1.7 References	37
Chapter 2. The Nagoya Protocol on Access to Genetic Resources and Benefit Sharing: <i>Best practices for users of Lactic Acid Bacteria</i>	
2.1 Abstract:	48
2.2 Introduction	49
2.3 Methodology	51

2.4 Best practices	51
2.4.1 Access to Genetic Resources	51
2.4.2 Scope of the Nagoya Protocol	52
2.4.3 Origin of the material	54
2.4.4 Due diligence requirements	54
2.5 Discussion	55
2.5.1 Bilateral negotiations	55
2.5.2 Equivocality of the Nagoya Protocol	56
2.5.3 Origin of genetic resources	57
2.6 Recommendations	57
2.7 Conclusion	59
2.8 Acknowledgments	59
2.9 Declaration of Interests	59
2.10 Reference list	60

Chapter 3. The underexposed role of food matrices in probiotic products: *reviewing the relationship between carrier matrices and product parameters.*

3.1 Abstract:	66
3.2 Introduction	67
3.3 Methodology	68
3.4 Important product parameters	69
3.5 Available probiotic products	72
3.5.1 Fermented Milk (Yogurt)	73
3.5.2 Cheese	75
3.5.3 Ice-cream	77
3.5.4 Probiotic meat products	78
3.5.5 Fruit and vegetable juices	79
3.5.6 Oats and cereals	80
3.5.7 Drying techniques	81
3.6 Comparing probiotic matrices	82
3.6.1 Shelf-life	83
3.6.2 GIT Survival	85
3.6.3 Colonization	88
3.6.4 Clinical Efficacy	89
3.7 Conclusions	90
3.8 Disclosure Statement	92

3.9 Appendix:	92
3.10 References	93

Chapter 4. Probiotics for healthy ageing: *Innovation barriers and opportunities for bowel habit improvement in nursing homes*

4.1 Abstract	106
4.2 Introduction	107
4.3 Methods	108
4.4 Results and discussion	110
4.4.1 Prevalence of constipation and diarrhoea in nursing homes: the underlying unmet need within the valorisation cycle	110
4.4.2 The valorisation cycle: science	110
4.4.3 Efficacy of probiotics: Proof of concept within the valorisation cycle	112
4.4.4 Safety evaluation of probiotics within the elderly: business development within the valorisation cycle	114
4.4.5 Customer feedback within the valorisation cycle: cost reduction.	115
4.5 Conclusions	116
4.6 References	117

Chapter 5. Economic Potential of Probiotic Supplementation in Institutionalized Elderly with Chronic Constipation

5.1 Abstract	122
5.2 Introduction	123
5.3 Methodology	124
5.3.1 Model	124
5.3.2 Survey	127
5.3.3 Literature search	128
5.3.4 Quantitative Data Synthesis	128
5.4 Results & Discussion	129
5.4.1 Survey respondents' characteristics	129
5.4.2 The conventional treatment expenditures	130
5.4.3 Constipation prevalence	132
5.4.4 Probiotic supplementation costs	132
5.4.5 The lower probiotic efficacy limit	134
5.4.6 Probiotic efficacy in clinical research	139
5.4.7 Economic potential of probiotic supplementation	140
5.5 Conclusion and Recommendations	140
5.6 Further considerations:	141
5.7 Disclosure Statement:	141
5.8 Online Appendix Material	142

5.9 Reference list	143
--------------------	-----

Chapter 6. Probiotics for Improving Quality of Life in Ulcerative Colitis: *Exploring the Patient Perspective*

6.1 Abstract	150
6.2 Introduction	151
6.3 Methods	153
6.3.1 Interview participants	153
6.3.2 Probiotic formulation	154
6.3.3 Interview design	154
6.3.4 Primary study parameters	154
6.3.5 Data-processing and -analysis	155
6.4 Results	155
6.4.1 Interview participants	155
6.4.2 Impact of ulcerative colitis on patients' quality of life	156
6.4.3 Probiotics for improving patients' quality of life	159
6.5 Conclusion and discussion	165
6.6 Study and findings in context	166
6.7 Limitations and considerations for future research	169
6.8 Acknowledgements	171
6.9 Ethics statement	172
6.10 Appendix	172
6.11 References	173

Chapter 7. Medical doctors' perceptions on probiotics: *Lack of efficacy data hampers innovation*

7.1 Abstract	180
7.1.1 Graphical abstract	181
7.2 Introduction	181
7.3 Methodology	182
7.3.1 Data collection	182
7.3.2 Study Population	183
7.3.3 Statistical Analysis	183
7.4 Results	183
7.4.1 Survey respondents' characteristics	184
7.4.2 Nutritional and Probiotic Advice	184
7.4.3 Indications for Probiotic Advice	187
7.4.4 Reasons Not to Advise Probiotics	187
7.4.5 Perceived Knowledge, Safety and Efficacy	187

7.4.6 Information Sources	189
7.4.7 Information Sources: Subgroup Analysis	190
7.4.8 Future Information: Sources	192
7.4.9 Future Information: Types	192
7.4.10 Future Information: Subgroup Analysis	193
7.5 Discussion & Conclusion	193
7.6 Limitations	194
7.7 Acknowledgements	195
7.8 Disclosure Statement	195
7.9 References	196

Chapter 8. European General Practitioners perceptions on probiotics: *Results of a multinational survey.*

8.1 Abstract	203
8.2 Introduction	203
8.3 Methodology	204
8.3.1 Data collection	204
8.3.2 Study population	204
8.3.3 Statistical analysis	204
8.4 Results	205
8.4.1 Survey respondents' characteristics	205
8.4.2 Nutritional and probiotic advice	206
8.4.3 Indications for probiotic advice	206
8.4.4 Perceived knowledge, safety and efficacy	207
8.5 Discussion and conclusion	209
8.6 Limitations	211
8.7 Disclosure statement	212
8.8 Acknowledgements	212
8.9 Formatting of funding sources	212
8.10 References	213

Chapter 9. Probiotic research priorities for the healthy adult population: *A review on the health benefits of Lactobacillus rhamnosus GG and Bifidobacterium animalis subspecies lactis BB-12*

9.1 Abstract	218
9.2 Introduction	219
9.3 Methods	220
9.4 Results and discussion	221
9.4.1 Results of literature search	221

9.4.2 Potential mechanism of action	224
9.4.3 Antibiotic-associated diarrhea	227
9.4.4 Irritable bowel syndrome	230
9.4.5 Bowel function	231
9.4.6 Microbiota balance	235
9.4.7 Immune support	239
9.4.8 Vaginal/urogenital health	246
9.4.9 Respiratory infections	247
9.4.10 Metabolism regulation in pregnancy	251
9.4.11 Oral health	254
9.5 Conclusion	255
9.6 Acknowledgements	255
9.7 Disclosure Statements	256
9.8 Online Appendix Material	256
9.9 References	257
Chapter 10. Discussion & conclusion	
10.1 Outline	274
10.2 Critical challenges in the development of probiotic applications	275
10.2.1 Key findings: Access to genetic resources	275
10.2.2 Key findings: Production & packaging	276
10.2.3 Recommendations	277
10.3 Barriers and opportunities for bowel habit improvement in nursing homes	277
10.3.1 Key findings	277
10.3.2 Recommendations	279
10.4 Perceptions of physicians and patients towards probiotics	279
10.4.1 Key findings	280
10.4.2 Recommendations	281
10.5 Research priorities for health claim approval in the adult population	281
10.5.1 Key findings	281
10.5.2 Recommendations	283
10.6 Validity & limitations	283
10.7 Summary & conclusion	285
10.8 References	289
List of abbreviations	294
About the author	297
Dankwoord	298